During the 2018 Annual Meeting of the Connective Tissue Oncology Society, Anette Duensing, MD, assistant professor of pathology at University of Pittsburgh, discusses the need for further investigation into how treatment type impacts perceived cognitive function in patients with gastrointestinal stromal tumor.
During the 2018 Annual Meeting of the Connective Tissue Oncology Society, Anette Duensing, MD, assistant professor of pathology at University of Pittsburgh, discussed her work on a large, web-based survey of perceived cognitive impairments in patients with gastrointestinal stromal tumor (GIST).
The survey found that, among 485 respondents, nearly two-thirds reported cognitive impairments that had impacted their quality of life. These impairments tended not to correlate with factors including fatigue, sleep disturbance, pain, or emotional distress, suggesting a need for more research.
Among the hypotheses in the study were that long-term treatment with TKI therapy could negatively impact cognitive function. Dr. Duensing discusses the need for further investigation into the potential impact on cognitive function among different treatment types, such as TKI inhibitorslike imatinib (Gleevec)—versus monoclonal antibodies—like olaratumab (Lartruvo) —in this context.
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More